Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMOkids study of Kimozo pediatric oral temozolomide suspension
NL-OMON50808Phase 2Active, not recruiting
- Sponsor
- ORPHELIA Pharma
- Start
- Sep 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in malignant glioma, glioblastoma (GBM), anaplastic astrocytoma (AA) and 5 more, sponsored by ORPHELIA Pharma. Primary endpoints: Temozolomide apparent clearance, Temozolomide apparent volume of distribution and 2 more. Started Sep 2022; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
malignant gliomaglioblastoma (GBM)anaplastic astrocytoma (AA)neuroblastomamedulloblastoma
Beyond the preview
Go deeper on NL-OMON50808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50808.